Opus Genetics (IRD) Gains from Sales and Divestitures (2018 - 2025)
Opus Genetics (IRD) reported Gains from Sales and Divestitures of $664734.0 for Q4 2025, up 111.59% year-over-year from $314162.0 in Q4 2024, and up 138.38% quarter-over-quarter from $278858.0 in Q2 2025.
Opus Genetics (IRD) Gains from Sales and Divestitures (2018 - 2025) Analysis & Trends
Opus Genetics (IRD) has 6 years of Gains from Sales and Divestitures data on file, last reported at $664734.0 in Q4 2025.
- Gains from Sales and Divestitures for Q4 2025 came in at $664734.0, up 111.59% year-over-year; the trailing twelve-month figure through Dec 2025 was $664734.0 (up 111.59% YoY), and the FY2025 annual result was $664734.0, up 111.59% from the prior year.
- Gains from Sales and Divestitures climbed to $664734.0 in Q4 2025 per IRD's latest filing, from $278858.0 in the prior quarter.
- Over five years, Gains from Sales and Divestitures peaked at $664734.0 in Q4 2025 and troughed at $33614.0 in Q2 2023.
- A 4-year average of $144306.3 and a median of $40000.0 in 2021 frame the typical range for Gains from Sales and Divestitures.
- The sharpest annual moves came in 2024 and 2025: Gains from Sales and Divestitures surged 834.62% in 2024, then jumped 111.59% in 2025.
- A 4-year view of Gains from Sales and Divestitures shows it stood at $40000.0 in 2021, then dropped by 15.96% to $33614.0 in 2023, then surged by 834.62% to $314162.0 in 2024, then surged by 111.59% to $664734.0 in 2025.
- Business Quant data shows IRD's Gains from Sales and Divestitures at $664734.0 in Q4 2025, $278858.0 in Q2 2025, and $102676.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Opus Genetics | 355.39 Mn | 295.43 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 664,734.00 |
| Dec 31, 2025 | 664,734.00 |
| Jun 30, 2025 | 278,858.00 |
| Jun 30, 2025 | 278,858.00 |
| Mar 31, 2025 | 102,676.00 |
| Mar 31, 2025 | 102,676.00 |
| Dec 31, 2024 | 314,162.00 |
| Dec 31, 2024 | 314,162.00 |
| Sep 30, 2024 | 144,162.00 |
| Sep 30, 2024 | 144,162.00 |
| Jun 30, 2024 | 104,880.00 |
| Jun 30, 2024 | 104,880.00 |
| Mar 31, 2024 | 39,282.00 |
| Mar 31, 2024 | 39,282.00 |
| Dec 31, 2023 | 33,614.00 |
| Dec 31, 2023 | 33,614.00 |
| Jun 30, 2023 | 33,614.00 |
| Jun 30, 2023 | 33,614.00 |
| Dec 31, 2021 | 40,000.00 |
| Dec 31, 2021 | 40,000.00 |